Ebenezer (@BackwaterBio) profile picture

Private biotech

Joined February 2016
Q2 13-F's with new initiations for $AMLX
90
Replying to @satvik_93
From a sell-side report this morning
5
310
Great visual on $SPCX IPO from @axios
331
Understood. I'm seeing the attached in my FS alerts and just wondering if the highlighted part is the only context or if FS +/- IQVIA (I have access to both) let's you figure out the granular numbers
1
1
140
Replying to @BoringBiz_
From the same book (easiest to pull the quote from Chat):
10
433
This was a weird year
1
139
Replying to @grhyasen
Follows a general decline in EV/peak sales multiples too
32
Happy Benefits Enrollment Day to those who celebrate
43
Replying to @robkhenderson
All Love Is Lost - Architects
47
Replying to @PersimmonTI @Nature
Generally deal activity has been picking up since Q4/Q1. Tough sell on valuation premiums now though vs that time period
16
Replying to @paras_biotech
Needham had a report on this too. Generally 1day premiums trending down over time, along with EV/Peak sales $XBI
242
Replying to @kevg1412
Erik Larson GOAT
1
38
Interesting times: "US VC secondary transactions totaled $61.1 billion from June 2024 to June 2025, leapfrogging IPO exit value of $58.8 billion over the same period, according to PitchBook data."
60
Given the mRNA conversations recently, I thought this poll from @bradloncar in the depths of the pandemic was appropriate to resurface. I'll note ofc that deciding whether something will "work" is different than whether it should be studied.
1
74
Replying to @CloisterRes
Kalshi at one point had predictions for >2500 cases...
1
67
Replying to @AppleHelix
Nice story here from the team (podcast version also available). I didn't appreciate the financial acumen prior youtu.be/iyVAoPejafY?si=hTEM…
1
4
370
Couple nice images here on the historical M&A landscape in biotech / pharma, from Needham $XBI $IBB
94